Your browser doesn't support javascript.
loading
Neutralizing Antibody Sample Testing and Report Harmonization.
Jani, Darshana; Gunsior, Michele; Marsden, Robin; Cowan, Kyra J; Irvin, Susan C; Hay, Laura Schild; Ward, Bethany; Armstrong, Luke; Azadeh, Mitra; Cao, Liching; Carmean, Rebecca; DelCarpini, Jason; Dholakiya, Sanjay L; Hays, Amanda; Hosback, Sarah; Hu, Zheng; Kulagina, Nadia; Kumar, Seema; Lai, Ching Ha; Lichtfuss, Marit; Liu, Hsing-Yin; Liu, Susana; Mozaffari, Reza; Pan, Luying; Pennucci, Jason; Poupart, Marie-Eve; Saini, Gurleen; Snoeck, Veerle; Storey, Kristine; Turner, Amy; Vainshtein, Inna; Verthelyi, Daniela; Wala, Iwona; Yang, Lili; Yang, Lin.
Afiliação
  • Jani D; Bioanalytical and Molecular Assays, Moderna, 325 Binney Street, Cambridge, Massachusetts, USA. darshana.jani@modernatx.com.
  • Gunsior M; Translational Sciences, Astria Therapeutics, Boston, Massachusetts, USA.
  • Marsden R; Revelation Biosciences, San Diego, California, USA.
  • Cowan KJ; Drug Metabolism & Pharmacokinetics, New Biological Entities, Merck KGaA, Darmstadt, Germany.
  • Irvin SC; Bioanalytical Sciences, Regeneron Pharmaceuticals, Tarrytown, New York, USA.
  • Hay LS; Bioanalytical Lab, PPD Clinical Research Business, Thermo Fisher Scientific, Richmond, Virginia, USA.
  • Ward B; Bioanalytical Lab, PPD Clinical Research Business, Thermo Fisher Scientific, Richmond, Virginia, USA.
  • Armstrong L; Bioanalytical Operations, BioAgilytix Labs, Durham, North Carolina, USA.
  • Azadeh M; Bioanalytical and Biomarker Development, Ultragenyx Pharmaceutical, Inc, Novato, California, USA.
  • Cao L; Biomarker and BioAnalytical Sciences, Sangamo Therapeutics, Brisbane, California, USA.
  • Carmean R; Bioanalytical Lab, PPD Clinical Research Business, Thermo Fisher Scientific, Richmond, Virginia, USA.
  • DelCarpini J; Bioanalytical Sciences, Moderna, Cambridge, Massachusetts, USA.
  • Dholakiya SL; Non-Clinical Disposition and Bioanalysis, Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Hays A; Scientific Office, BioAgilytix Labs, Durham, North Carolina, USA.
  • Hosback S; Research and Clinical Bioanalytics, CSL, Melbourne, Australia.
  • Hu Z; Translational Safety & Bioanalytical Science, Amgen Inc, Thousand Oaks, California, USA.
  • Kulagina N; Pharmaceutical Development Services, Smithers, Gaithersburg, Maryland, USA.
  • Kumar S; DMPK and Bioanalysis, Pioneering Medicines at Flagship Pioneering, Cambridge, Massachusetts, USA.
  • Lai CH; Bioanalytical Sciences, Regeneron Pharmaceuticals, Tarrytown, New York, USA.
  • Lichtfuss M; Research and Clinical Bioanalytics, CSL, Melbourne, Australia.
  • Liu HY; Janssen Research & Development LLC, Spring House, Montgomery County, Pennsylvania, USA.
  • Liu S; Clinical Pharmacology, Biologics & Immunogenicity Clinical Assay Group, Pfizer Inc, Kirkland, Quebec, Canada.
  • Mozaffari R; Bioanalysis, Immunogenicity & Biomarkers (BIB), IVIVT, Research, GSK, Collegeville, Pennsylvania, USA.
  • Pan L; Takeda Development Center Americas Inc, Cambridge, Massachusetts, USA.
  • Pennucci J; Bioanalytical Sciences, Moderna, Cambridge, Massachusetts, USA.
  • Poupart ME; Immunology, Charles River Laboratories, Senneville, Quebec, Canada.
  • Saini G; Drug Metabolism & Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut, USA.
  • Snoeck V; Translational Biomarkers and Bioanalysis, UCB Biopharma SRL, 1420, Braine-L'Alleud, Belgium.
  • Storey K; Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc, Rahway, New Jersey, USA.
  • Turner A; Pharmaceutical Development Services, Smithers, Gaithersburg, Maryland, USA.
  • Vainshtein I; Discovery and Translational Research, Exelixis, Alameda, California, USA.
  • Verthelyi D; Office of Pharmaceutical Quality Research, Division IV, Center for Drugs Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
  • Wala I; Translational Safety and Bioanalytical Sciences, Amgen, Thousand Oaks, California, USA.
  • Yang L; Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA.
  • Yang L; Bioanalytical Sciences, REGENXBIO Inc, Rockville, Maryland, USA.
AAPS J ; 26(4): 80, 2024 Jul 12.
Article em En | MEDLINE | ID: mdl-38992280
ABSTRACT
Immunogenicity testing and characterization is an important part of understanding the immune response to administration of a protein therapeutic. Neutralizing antibody (NAb) assays are used to characterize a positive anti-drug antibody (ADA) response. Harmonization of reporting of NAb assay performance and results enables efficient communication and expedient review by industry and health authorities. Herein, a cross-industry group of NAb assay experts have harmonized NAb assay reporting recommendations and provided a bioanalytical report (BAR) submission editable template developed to facilitate agency filings. This document addresses key bioanalytical reporting gaps and provides a report structure for documenting clinical NAb assay performance and results. This publication focuses on the content and presentation of the NAb sample analysis report including essential elements such as the method, critical reagents and equipment, data analysis, study samples, and results. The interpretation of immunogenicity data, including the evaluation of the impact of NAb on safety, exposure, and efficacy, is out of scope of this publication.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Neutralizantes Limite: Humans Idioma: En Revista: AAPS J Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Neutralizantes Limite: Humans Idioma: En Revista: AAPS J Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos
...